Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Six puppies ‘in distress’ rescued by police in Hamilton

October 14, 2026

Anthropic’s self-replicating AI warning is alarming deja vu

October 14, 2026

A tough housing market could revive multigenerational homes, poll suggests

October 14, 2026

Canadian musician Joni Mitchell becomes U.S. citizen

October 14, 2026

Apple’s new Find My-compatible remote will also work with your old Apple TV

October 14, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Biopharmaceutical Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030: Growing Demand for Novel Treatments in Oncology, Autoimmune, and Genetic Disorders
Press Release

Biopharmaceutical Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030: Growing Demand for Novel Treatments in Oncology, Autoimmune, and Genetic Disorders

By News RoomDecember 2, 20253 Mins Read
Biopharmaceutical Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030: Growing Demand for Novel Treatments in Oncology, Autoimmune, and Genetic Disorders
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) — The “Biopharmaceutical Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.

The Global Biopharmaceutical Market, valued at USD 435.82 Billion in 2024, is projected to experience a CAGR of 8.76% to reach USD 721.31 Billion by 2030.

Biopharmaceuticals are therapeutic agents derived from biological sources using biotechnological methods, encompassing products such as monoclonal antibodies, vaccines, gene therapies, and recombinant proteins, designed to treat a wide array of complex diseases. The global market is primarily driven by the escalating prevalence of chronic conditions, continuous advancements in biotechnology, and an expanding aging population worldwide.

The global biopharmaceutical market is significantly propelled by the increasing global prevalence of chronic and rare diseases. The rising incidence of conditions such as cancer, autoimmune disorders, and various genetic diseases creates an urgent demand for novel and effective therapeutic solutions that biopharmaceuticals are uniquely positioned to offer. These complex diseases often present considerable unmet medical needs, driving research and development towards treatments that promise higher efficacy and improved patient outcomes.

Key Market Challenges

A significant challenging factor hampering the growth of the Global Biopharmaceutical Market is the exceptionally high costs associated with extensive research and development initiatives. Developing novel biopharmaceutical products requires substantial capital investment due to the intricate scientific processes and advanced technologies involved. According to PhRMA’s 2023 annual report, member companies invested $102.3 billion in research and development, underscoring the immense financial burden required for innovation in this sector. These costs often translate into lengthy funding cycles, consuming significant resources before any market returns can be realized.

Key Market Trends

The integration of advanced artificial intelligence into drug development processes is fundamentally reshaping the global biopharmaceutical market. This trend is driven by AI’s ability to significantly accelerate discovery timelines and enhance the precision of therapeutic interventions. According to the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical industry invested an estimated €55.00 billion in research and development across Europe in 2024, a considerable portion of which is now being leveraged into AI-driven platforms. These technologies allow for rapid analysis of complex biological data, prediction of molecular interactions, and optimization of compound design, thereby streamlining preclinical research.

Key Attributes:

Report Attribute Details
No. of Pages 180
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $435.82 Billion
Forecasted Market Value (USD) by 2030 $721.31 Billion
Compound Annual Growth Rate 8.7%
Regions Covered Global


Report Scope:

Key Market Players Profiled:

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd.

By Product Type:

  • Monoclonal Antibodies
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Recombinant Hormones
  • Vaccines
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Others

By Therapeutic Application:

  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

For more information about this report visit https://www.researchandmarkets.com/r/c6k202

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Anthropic’s self-replicating AI warning is alarming deja vu

October 14, 2026

A tough housing market could revive multigenerational homes, poll suggests

October 14, 2026

Canadian musician Joni Mitchell becomes U.S. citizen

October 14, 2026

Apple’s new Find My-compatible remote will also work with your old Apple TV

October 14, 2026

Latest News

Toronto police to give update on 2 Canadian soldiers facing 49 charges

October 14, 2026

Why Canada’s caregivers say their retirement plans are being ‘decimated’

October 14, 2026

Amazon Alexa Tablet 12 Pro review: almost the Android tablet we needed

October 14, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version